Reported 3 months ago
Meghan Fitzgerald, CEO of Grey Ghost Advisors, expresses an 'extremely bullish' outlook on the biopharma industry, citing that significant deals totaling $1 billion have occurred this year. She notes that major pharmaceutical companies like Pfizer and Merck have surpassed earnings expectations, with Pfizer's stock dropping 50% since its peak in 2021, indicating opportunities for investors due to low price multiples compared to expected returns. Fitzgerald believes that the industry fundamentals remain strong, regardless of the upcoming elections.
Source: YAHOO